CClinicalTrials.gg
RecruitingNCT05098340CRASTUpdated Aug 6, 2024

Circulating circRNA in Acute Ischemic Stroke

An observational study in Acute Ischemic Stroke, sponsored by The Affiliated Hospital of Xuzhou Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-06.

Sponsored by The Affiliated Hospital of Xuzhou Medical University · Observational

From the registry’s dates

  • Primary completion was expected by Oct 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Oct 2020; still recruiting 6 years later.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

CRAST is to analyze the expression pattern of circular RNA (circRNA) by bioinformatics analysis in patients with acute ischemic stroke and healthy control. The candidate circRNA will be verified as biomarkers for the detection and prognosis of acute ischemic stroke.

Read the detailed description

Circular RNAs have been highlighted to be involved in the pathological process of ischemic stroke (IS). The purpose of this protocol will investigate the expression pattern of circular RNA (circRNA) by bioinformatics analysis in patients with acute ischemic stroke and healthy control. The candidate circRNA will be verified as biomarkers for the detection and prognosis of acute ischemic stroke. Distinctive expression patterns of circRNA will be identified by individual quantitative real time polymerase chain reaction (qRT-PCR). A diagnostic or predictive model will be established using logistic regression. The panel of these altered circRNAs may be associated with acute IS and could serve as a novel diagnostic or predictive method.

02

Conditions studied

  • Acute Ischemic Stroke

Keywords

  • circRNA
03

In context

Stroke

7,283 studies on the registry are indexed under Stroke; 2,013 are open to participants now.

This study's planned enrollment of 500 is above the median of 160 across 1,692 observational studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

The Affiliated Hospital of Xuzhou Medical University is the lead sponsor of 66 studies on the registry; 31 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

There will be 100 patients suspected of AIS (such as transient ischemic attack), 300 AIS patients and 100 Healthy controls,whose data will be applied for construction and validation of diagnostic and predictive models of circRNA from the circulating blood.

Inclusion criteria

  • Aged 18 years or older
  • Confirmed acute ischemic stroke by a diffusion-weighted imaging-position lesion on magnetic resonance imaging (MRI) and a new lesion on a brain computed tomography (CT) scan
  • Within 72 hours of symptom onset
  • Good performance status
  • Signed an approved informed consents

Exclusion criteria

Exclusion Criteria:

  • a history of hemorrhagic infarction, chronic kidney/liver diseases, peripheral arterial occlusive disease, active malignant disease, and inflammatory or infectious diseases
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
90 Days
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • AIS group

    This group includes patients with acute ischemic stroke (AIS).

    Genetic: Quantitative Real-time polymerase chain reaction

  • HC group

    This group includes healthy controls (HC).

    Genetic: Quantitative Real-time polymerase chain reaction

Interventions

  • GeneticQuantitative Real-time polymerase chain reaction

    Quantitative Real-time polymerase chain reaction of circular RNA (circRNA).

06

What researchers measure

Primary outcomes

  1. Differential expression pattern of circRNA

    Differential expression pattern of circular RNA (circRNA) will be compared between AIS group and HC group, thus candidate circRNA will be verified as biomarkers for the detection and prognosis of AIS.

    Time frame: 90 days

Secondary outcomes

  1. Dynamic changes of circRNA during the follow-up period

    Dynamic changes of circRNA will be explored before and after endovascular therapy

    Time frame: 90 days

  2. Correlation of circRNA and stroke-associated infection

    Correlation of circRNA and stroke-associated infection will be explored in acute ischemic stroke.

    Time frame: 30 days

  3. Correlation of circRNA and inflammatory factors in acute ischemic stroke

    Correlation of circRNA and inflammatory factors on admission will be explored in acute ischemic stroke.

    Time frame: 7 days

  4. Prognostic value of circRNA in acute ischemic stroke

    The prognosis of AIS patients will be analyzed between differential expressed candidate circRNA after they have completed the systematic therapy.

    Time frame: 90 days

07

Study locations

1 of 1 sites recruiting
  • Department of Neurology
    Xuzhou, Jiangsu, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05098340
Lead sponsor
The Affiliated Hospital of Xuzhou Medical University
Responsible party
Sponsor
First posted
Oct 28, 2021
Start date
Oct 1, 2020
Primary completion
Oct 30, 2024 (estimated)
Completion
Oct 30, 2024 (estimated)
Last update
Aug 6, 2024

Study contacts

Xingzhi Wang, MD
Contact
wxz1220@126.com
0086-13852000759

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion